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A randomised controlled crossover trial
investigating the short-term effects of
different types of vegetables on vascular
and metabolic function in middle-aged and
older adults with mildly elevated blood
pressure: the VEgetableS for vaScular
hEaLth (VESSEL) study protocol
Emma L. Connolly1, Catherine P. Bondonno1,2, Marc Sim1,2, Simone Radavelli-Bagatini1, Kevin D. Croft2,
Mary C. Boyce3, Anthony P. James4, Karin Clark4, Reindolf Anokye1, Nicola P. Bondonno1,2, Richard J. Woodman5,
Amanda Devine1, Seng Khee Gan2, Carl J. Schultz2, Richard F. Mithen6, Joshua R. Lewis1,2,7,
Jonathan M. Hodgson1,2† and Lauren C. Blekkenhorst1,2*†
Abstract
Background: A diet rich in fruits and vegetables is recommended for cardiovascular health. However, the majority of
Australians do not consume the recommended number of vegetable servings each day. Furthermore, intakes of vegetables
considered to have the greatest cardiovascular benefit are often very low. Results from prospective observational studies
indicate that a higher consumption of cruciferous vegetables (e.g. broccoli, cabbage, cauliflower) is associated with lower
cardiovascular disease risk. This may be due to the presence of specific nutrients and bioactive compounds found almost
exclusively, or at relatively high levels, in cruciferous vegetables. Therefore, the aim of this randomised controlled crossover
trial is to determine whether regular consumption of cruciferous vegetables results in short-term improvement in measures
related to cardiovascular disease risk, including ambulatory blood pressure, arterial stiffness, glycaemic control, and circulating
biomarkers of oxidative stress and inflammation.
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Methods: Twenty-five participants (50–75 years) with mildly elevated blood pressure (systolic blood pressure 120–160
mmHg) will complete two 2-week intervention periods in random order, separated by a 2-week washout period. During the
intervention period, participants will consume 4 servings (~ 300 g) of cruciferous vegetables per day as a soup (~ 500–600
mL/day). The ‘control’ soup will consist of other commonly consumed vegetables (potato, sweet potato, carrot, pumpkin).
Both soups will be approximately matched for energy, protein, fat, and carbohydrate content. All measurements will be
performed at the beginning and end of each intervention period.
Discussion: The findings of this study will provide evidence regarding the potential cardiometabolic health benefits of
cruciferous vegetables, which may contribute to the revision of dietary and clinical guidelines.
Trial registration: The trial was registered with the Australian New Zealand Clinical Trial Registry on 19th September 2019
(ACTRN12619001294145).
Keywords: Blood pressure, Cardiovascular disease, Cruciferous vegetables, Glycaemic control, Inflammation, Oxidative stress,
Arterial stiffness
Background
Cardiovascular disease is the leading cause of death in
Australia, accounting for 27% of all deaths in 2017 [1].
Furthermore, cardiovascular disease is the largest disease
contributor to Australian health expenditure, costing the
healthcare system approximately $5 billion (11%) each
year [2]. One of the most important modifiable risk fac-
tors for cardiovascular disease is an unhealthy diet [3]. It
is recommended that individuals consume high amounts
of vegetables, fruits, mono- and polyunsaturated fatty
acids, and fibre, whilst limiting their intake of total and
saturated fat, cholesterol, and salt. Like cardiovascular
disease, the prevalence of type 2 diabetes is increasing
worldwide [4]. Adults with type 2 diabetes have a two-
to three-fold increased risk of experiencing a heart at-
tack or stroke [5]. Factors such as high blood pressure,
high blood cholesterol, and overweight and obesity play
a major role in the development of cardiometabolic dis-
eases, further highlighting the importance of a healthy
diet to assist in the maintenance of these factors within
healthy parameters [6].
Despite knowledge of the importance of vegetables in
the diet and the inclusion of such recommendations in
dietary guidelines [7], only 7.5% of Australian adults con-
sume the recommended 5–6 daily servings of vegetables
(375–450 g) [8]. This is similar in many other countries [9,
10]. Inadequate vegetable intake has been attributed to 17
and 10% of the total burden of stroke and coronary heart
disease, respectively [11]. In Australia, it has been esti-
mated that total health expenditure could be reduced by
$1.4 billion per year if Australians consumed the recom-
mended 5–6 servings of vegetables daily [12].
Although current dietary guidelines recommend a high
intake of all vegetables, evidence suggests that not all
vegetables offer equal health benefits. In particular, stud-
ies have shown that some vegetables may be more pro-
tective against cardiovascular disease than others.
Results of prospective observational studies indicate that
higher consumption of vegetables from the Brassicaceae
family (also called Cruciferae, known as cruciferous veg-
etables) is associated with lower cardiovascular disease
risk [3, 13–15]. These vegetables are commonly known
as cruciferous vegetables and include broccoli, cabbage,
cauliflower, Brussels sprouts, kale, and bok choy. There
are a number of nutrients and bioactive compounds
found almost exclusively, or at relatively high levels, in
cruciferous vegetables. These include, but are not limited
to, organosulfur compounds, nitrate, and phylloquinone
(vitamin K1). Recent studies have highlighted the poten-
tial cardiovascular health benefits of these compounds
[13–18].
Extensively studied for their anti-cancer properties [15],
organosulfur compounds have also been reported to have
potential cardiovascular health benefits [13–15]. These
compounds may slow atherosclerotic plaque progression
through a reduction in inflammation and reactive oxygen
species [15]. In addition to the potential benefits of orga-
nosulfur compounds found in cruciferous vegetables, ni-
trate has been shown to reduce blood pressure in healthy
populations [19] and potentially lower the risk of cardio-
vascular disease clinical endpoints [16–18]. Through the
enterosalivary nitrate-nitrite-nitric oxide pathway, dietary
nitrate is reduced to nitrite in the oral cavity, which then
enters the circulation upon swallowing and is converted to
nitric oxide; a cell signalling molecule important in regu-
lating vascular tone and integrity [20]. Currently, there is
limited evidence regarding dietary phylloquinone intake
and cardiovascular disease. However, some studies have
suggested an inverse relationship [21, 22] and there is
emerging evidence of the potential role of phylloquinone
in inhibiting vascular calcification [23].
If cruciferous vegetables are indeed more superior
than other vegetables in lowering risk of cardiovascular
disease then targeted dietary modification including an
increased intake of cruciferous vegetables has the poten-
tial to play an important role in cardiovascular disease
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prevention. Overall, further evidence is required to
evaluate the cardiovascular health benefits of cruciferous
vegetables and their bioactive constituents. Intervention
studies are needed to establish the benefit of these vege-
tables on cardiovascular health and to determine
whether cruciferous vegetables are superior to other
more commonly consumed vegetable types. At present,
there are no intervention trials comparing the cardiovas-
cular health benefits of these vegetable types. The pro-
posed study will establish the efficacy for an increase in
cruciferous vegetable intake to improve measures related
to cardiovascular disease risk, including blood pressure,




To determine if cruciferous vegetables are superior in
lowering blood pressure than more commonly con-
sumed vegetables in middle-aged and older adults with
mildly elevated blood pressure.
Secondary objectives
To determine if cruciferous vegetables are superior in
improving arterial stiffness, glycaemic control, oxidative
stress, and inflammation than more commonly con-
sumed vegetables in middle-aged and older adults with
mildly elevated blood pressure.
Research hypotheses
The study aims to test the following hypotheses:
1. Daily consumption of cruciferous vegetables, in
comparison to other commonly consumed
vegetables, will lower ambulatory blood pressure in
middle-aged and older adults with mildly elevated
blood pressure.
2. Daily consumption of cruciferous vegetables, in
comparison to other commonly consumed
vegetables, will improve arterial stiffness, glycaemic
control, and circulating biomarkers of oxidative
stress and inflammation in middle-aged and older
adults with mildly elevated blood pressure.
Trial design
The VEgetableS for vaScular hEaLth (VESSEL) study
protocol adheres to the Standard Protocol Items: Rec-
ommendations for Intervention Trials (SPIRIT) 2013
Statement (see Additional file 1) [24, 25]. The VESSEL
study is designed as a randomised, controlled, crossover
trial with two 2-week dietary intervention periods, sepa-
rated with a 2-week washout period. Participants will be
randomly assigned (1:1) to one of 2 sequence orders
using computer generated random numbers. All
participants will complete both dietary interventions.
Therefore, as participants will act as their own control,
this will remove any potential differences between sub-
jects and reduce the potential bias when estimating the
intervention effect. A detailed process evaluation will be
performed to assess the suitability, reliability, and imple-
mentation of all procedures involved in this study
(protocol in preparation).
Participants, interventions, and outcomes
Study setting
This study will be conducted at the Royal Perth Hospital
Research Foundation, School of Medical and Health Sci-
ences, Edith Cowan University. The Royal Perth Hospital
Research Foundation is located in Perth CBD, Australia.
Eligibility criteria
Participants must provide written informed consent be-
fore any physical assessments occur (see Additional file 2
for sample Participant Information and Consent Form).
Inclusion criteria We will recruit ambulant
community-dwelling men and women aged between 50
and 75 years who have mildly elevated blood pressure
(systolic blood pressure 120–160 mmHg, inclusive, and
diastolic blood pressure < 100 mmHg).
Exclusion criteria Volunteers will be excluded from
participation based on the following criteria: body mass
index < 18.5 or ≥ 40 kg/m2; systolic blood pressure > 160
mmHg or < 120 mmHg; diastolic blood pressure > 100
mmHg; use of > 2 antihypertensive medications or ir-
regular use of nitric oxide donors, organic nitrites and
nitrates, and sildenafil and related drugs; diagnosed dia-
betes or fasting blood glucose > 6.5 mmol/L; fasting total
cholesterol > 8 mmol/L; current or recent (< 12months)
smoking; adhesive allergy; regular aspirin use; medica-
tion use for thrombosis or anticoagulants (Warfarin);
history of cardiovascular or peripheral vascular disease
(myocardial infarction, stroke, transient ischaemic attack,
amputation due to arterial insufficiency, any form of ar-
terial revascularisation, history of exertional angina or
claudication); psychiatric illness or other major illnesses,
such as cancer; alcohol intake > 100 g per week; current
or recent (within previous 6 months) significant weight
loss or gain (> 6% of body weight) or actively trying to
lose weight; pre-menopausal women; inability to attend
clinic/office visits; use of antibiotics (within previous 2
months); use of antibacterial mouthwash and not willing
to cease for trial duration; reported participation in night
shift work during the study period; and inability or un-
willingness to follow the study protocol. Volunteers with
specific dietary requirements, allergies, or intolerances
(e.g. following a low FODMAP diet) that will interfere
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with their ability to follow the dietary requirements of
the study will also be excluded.
Recruitment
Study investigators will continue to recruit participants
until an approximately equal proportion of males and fe-
males have been enrolled. The enrolment period will ex-
tend over 6 months or until adequate sample is reached.
Recruitment strategy Participants will be recruited
through a wide range of state and local media channels
including newspaper advertisements, media articles, and
radio interviews. All advertisements will have prior ap-
proval from the Edith Cowan University Human Re-
search Ethics Committee. Responses to inquiries about
participation will be answered by the study coordinator
(ELC) or a research assistant using a dedicated mobile
phone or email address that will be operational during
business hours. Volunteers interested in participating
will be sent an information pack that explains the study
in detail. The study coordinator (ELC) or a research as-
sistant will provide verbal consent from interested vol-
unteers willing to participant to be pre-screened over
the telephone. Participant will be pre-screened to deter-
mine eligibility for further physical screening at the
Royal Perth Hospital Research Foundation, Perth,
Australia. Physical screening will include anthropometric
measurements (height and weight), blood pressure mea-
surements, an electrocardiogram, and a fasting blood
test (lipid profile and glucose test). Blood pressure will
be assessed at this clinic screening visit using a CARES-
CAPE™ Dinamap v100 Vital Signs Monitor (GE Health-
care, Buckinghamshire, UK). Participants will be asked
to rest for 5 min before 5 blood pressure and heart rate
readings taken at 2-min intervals. The first measurement
will be excluded and the mean of the next 4 consecutive
readings will be used to determine resting blood pres-
sure. If blood pressure is found to be outside the eligible
range, volunteers will be excluded from the study and
will not undergo an electrocardiogram or a fasting blood
test.
Sample size
A sample size of 25 participants completing the trial has
been calculated based on the primary outcome of mean
24-h ambulatory systolic blood pressure. To allow for up
to 10% withdrawal rate, we plan to recruit 28 eligible
participants to this study. We have estimated > 90% reten-
tion based on our previous studies [26]. With α = 0.05, 25
participants will provide > 90% power to detect a 2.5
mmHg difference in mean 24-h ambulatory systolic blood
pressure. The power calculation is based on an SD of 14
mmHg for systolic blood pressure, a within-period correl-
ation between systolic blood pressure measurements of
0.6, a between period correlation of the mean systolic
blood pressure of 0.6, and a minimum of 40 BP measure-
ments over each 24 h period (up to 3 measures each hour
6 am-10 pm and up to 2 each hour 10 pm-6 am) [26]. This
calculation utilises the variance inflation factor (VIF) for-
mula for a cross-over trial of VIF=N*(1-ρ)/m, where N is
the number of subjects required for a parallel design, ρ is
the between period correlation (0.6), and m = 2 is the
number of visits per subject [27]. With α = 0.05, 25 partici-
pants will also provide > 90% power to detect a 0.30
mmol/l (~ 5%) difference in mean 2-h post-meal esti-
mated blood glucose concentration. This is based on
within-group SD of 1.5 mmol/L and a minimum of 80
glucose measures (2 meals per day with soup, for 14 days,
with a measure every 15min over 2 h) over each 2-week
period, and a within-subject correlation between measures
of r = 0.6.
Assignment of interventions
Allocation
Sequence generation Eligible participants will be ran-
domly assigned to one of 2 sequence orders with a 1:1
allocation using computer generated random numbers.
Concealment mechanism Fifty sealed opaque envelopes,
numbered 1–50, each containing one of the 2 sequence
orders for intervention diets will be used for randomisa-
tion by opening an envelope, in consecutive order, as par-
ticipants are entered into the study. The computer-
generated random numbers and sealed opaque envelopes
will be completed and held by a person independent of
study investigators.
Implementation The study coordinator will contact the
person independent of study investigators to obtain the
next available envelope once an individual is deemed eli-
gible. The envelope will be opened and the code will be
recorded.
Blinding
Due to the nature of the interventions given, participants
cannot be completely blinded to the interventions re-
ceived. Participants will be blinded to which soup is the
active or control. However, both soups will be different
in taste and appearance. Blinding will be used for all la-
boratory analyses.
Dietary interventions
Eligible participants will complete two 2-week dietary in-
terventions separated by a 2-week washout period where
participants will return to their usual diet. During each
2-week intervention period participants will consume
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standard lunch and dinner meals that will be provided
to standardise background diets.
The two 2-week dietary interventions will correspond
to:
1. Cruciferous vegetables (CRV, active): 4 servings (~
300 g) of cruciferous vegetables (broccoli, cabbage,
cauliflower, and kale) per day consumed as a soup
at lunch and dinner (~ 500–600 mL soup/day); and
2. other commonly consumed vegetables (OCV,
control): 4 servings (~ 300 g) of other commonly
consumed vegetables (potato, sweet potato, carrot,
and pumpkin) per day consumed as a soup at lunch
and dinner (~ 500–600 mL soup/day)
Four servings of vegetables (~ 300 g) daily represents
an achievable daily intake of these vegetables. It is ex-
pected that participants will have a background vege-
table intake of approximately 1–4 servings (~ 75–300 g)
per day during the intervention periods. Therefore, the
additional 4 servings of vegetables that the soups provide
will shift vegetable intake to at or above the recom-
mended 5–6 servings (375–450 g) per day.
Both active and control soups will be matched for en-
ergy (~ 600 kJ per serving). All vegetables will be boiled
prior to blending into soup. A small amount of potato
starch will be added to the CRV soup to approximately
match the carbohydrate content with the OCV soup.
There will be small differences in macronutrient content
per serving: protein (CRV ~ 10 g, OCV ~ 5 g), fat (CRV
~ 0.6 g, OCV ~ 0.3 g), carbohydrate (CRV ~ 19 g, OCV
~ 27 g), and fibre (CRV ~ 9 g, OCV ~ 6 g).
Soups will be prepared at Edith Cowan University,
Joondalup Campus, using standardized recipes and fro-
zen immediately for storage.
To limit background diet variation, participants will
consume frozen pre-prepared lunch and dinner meals
provided by study investigators. These meals will provide
approximately 1–4 servings (75–450 g) of background
vegetables per day. Slight variation in vegetable intake
between participants may occur, as participants will be
able to select meals based on personal preference. With
the exception of the intervention soups, participants will
be asked to consume the same foods during both inter-
vention periods. Participants will also be asked to repli-
cate exactly what they ate in the 24 h prior to each clinic
visit. This will allow us to directly compare the two
vegetable types in both intervention periods.
Two consumer representatives provided feedback on
the feasibility and palatability of the intervention soups.
Consumer Advocate, Corinna Musgrave, from the Con-
sumer and Community Health Research Network
assisted in finding the most appropriate consumer repre-
sentatives. Both consumers (male and female) attended
the Royal Perth Hospital Research Foundation, Perth,
Australia, for 1 hour. Each consumer was provided with
a $35 honorarium.
Modifications In the unforeseen circumstance that a
study participant needs to discontinue an assigned inter-
vention, whenever possible the participant will be
retained in the trial to enable follow-up data collection
and prevent missing data. Before re-commencing the
assigned intervention, participants will undergo a wash-
out period.
Adherence Food and nutrient intake will be assessed
daily throughout the intervention periods using dietary re-
cords. Participants will be asked to record their entire food
and beverage intake each day using the application “Re-
search Food Diary” (Xyris Software, Brisbane, Australia)
or via a paper-based record. We will also use self-reported
soup intake diaries and ask participants to return their
empty soup containers as a measure of soup compliance.
We will measure plasma carotenoids using high per-
formance liquid chromatography [28, 29]. Plasma carot-
enoids will be measured as a biomarker of vegetable
intake [30]. It is expected that total plasma carotenoids
will be increased substantially after both the CRV and
OCV interventions. However, the carotenoid profiles will
vary slightly due to the differences in individual caroten-
oids present in the different vegetables consumed. S-
methyl cysteine sulfoxide concentration in plasma sam-
ples will be used as a biomarker of CRV intervention
and will be measured using liquid chromatography-mass
spectrometry (LC-MS)/MS techniques as previously de-
scribed [31]. It is expected that plasma S-methyl cysteine
sulfoxide concentration will be increased after CRV
intervention, but not OCV intervention, and is therefore
a measure of CRV intervention compliance.
Concomitant care Participants will be asked to take
regular medications as per usual and refrain from par-
ticipating in any other research studies whilst undergo-
ing study requirements. If a participant is a regular
blood donor, the individual will be asked to postpone
donating blood until after the study has been completed.
Participant timeline
A schematic diagram of the trial design, procedures, and
stages is shown in Fig. 1. The trial consists of two 2-
week intervention periods, separated by a 2-week wash-
out period. Participants will attend 12 morning clinic
visits at the Royal Perth Hospital Research Foundation
over a 6 to 7-week period. Outcome assessments will be
taken at the beginning and end of each 2-week
intervention.
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Outcomes
Primary outcome The primary outcome of this study
will be the difference between interventions (CRV,
OCV) for 24-h ambulatory brachial systolic blood pres-
sure with the additional adjustment for pre-treatment
systolic blood pressure.
Secondary outcomes Secondary outcomes for this study
will be the difference between interventions (CRV,
OCV) with the additional adjustment for pre-treatment
values for the following:
 24-h ambulatory brachial diastolic blood pressure
 24-h ambulatory aortic systolic blood pressure
 24-h ambulatory aortic diastolic blood pressure
 24-h ambulatory augmentation index
 Mean continuous glucose (not adjusting for pre-
treatment values)
 Oxidative stress marker (plasma F2-Isoprostanes)
 Inflammatory markers (serum high sensitivity
interleukin-6 and high sensitivity C-reactive protein)
Data collection, management, and analysis
Data collection methods
All measurements, with the exception of glucose moni-
toring, will be performed at the beginning and end of
each 2-week intervention period. Glucose monitoring
will be continuous throughout each 2-week intervention
period.
Blood pressure Blood pressure will be assessed as 24-h
ambulatory blood pressure. Participants will be fitted with
an Oscar 2™ Ambulatory Blood Pressure Monitor (ABPM)
system (SunTech Medical Inc., Morrisville, NC, USA) by a
trained study investigator. Whilst wearing the monitor,
blood pressure (brachial and aortic) and heart rate will be
measured every 20min during the day (6 am – 10 pm)
and every 30min overnight (10 pm – 6 am). Use of the
monitor will be explained by a trained study investigator,
who will also instruct participants to continue daily activ-
ities and to avoid any vigorous exercise whilst wearing the
monitor. Blood pressure traces that are missing more than
20% of measurements will be excluded from the analyses.
If the initial tests are excluded, participants will be encour-
aged to repeat the test. Participants will use the same
blood pressure monitor each time.
Arterial stiffness Arterial stiffness will be assessed as
augmentation index (AIx). AIx is a measure of systemic
arterial stiffness that can be derived from aortic wave-
form data. This data can be obtained using the Sphyg-
moCor component found inside the Oscar 2™ ABPM
system (SunTech Medical Inc., Morrisville, NC, USA).
The same algorithm as used in the SphygmoCor XCEL
is used to obtain the AIx, but in an ambulatory setting
instead of resting setting.
Glycaemic control Participants will be fitted with a
Flash Glucose Monitoring System (Freestyle Libre;
Abbott Diabetes Care Inc., Alameda, CA, USA) for con-
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Anthropometry + + + + +
Blood sample + + + + +
24-hour ambulatory blood pressure/arterial stiffness + + + +
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Questionnaires + + + +
24-hour urine sample + + + +
Saliva/oral bacteria sample + + + +











Fig. 1 Schematic diagram of the trial design, procedures, and stages
Connolly et al. Nutrition Journal           (2020) 19:41 Page 6 of 11
periods. This system is comprised of two separate com-
ponents: a Freestyle Libre sensor and reader. The sensor
is small, water-resistant, and disposable, and is worn on
the back of the upper arm for up to 14 days. This auto-
matically measures glucose levels in the interstitial fluid
every minute using a subcutaneous, wired, enzyme glu-
cose sensing technology [32, 33] and stores data every
15 min for a period of 8 h. Stored glucose data is trans-
ferred to the reader by scanning the sensor. The sensor
does not require calibration and allows for accurate glu-
cose measurement without the requirement of a finger
prick [34]. The screen of the reader will be covered such
that participants will remain blinded to their glucose
readings throughout the study.
The reader is a compact, handheld device that displays
and stores up to 90 days of glucose data. After scanning
the sensor, the reader displays a current glucose reading,
data for the preceding 8 h (in graph form), and a trend
arrow indicating if glucose is increasing, decreasing, or
remaining steady. During the study, participants will be
asked to scan the sensor at least once every 8 h (morn-
ing, afternoon, and evening) during both intervention
periods to ensure all glucose data is captured for each
24-h period. Participants will record their diet and the
timing of each meal to allow for an accurate measure of
post-prandial glucose concentrations.
Circulating biomarkers of oxidative stress and
inflammation Fasting (≥12 h) blood samples will be col-
lected at the beginning and end of each intervention
period. F2-isoprostanes, a biomarker of oxidative stress,
will be measured in plasma samples as total (free plus es-
terified) F2-isoprostanes using electron-capture negative-
ion gas chromatography-mass spectrometry, as previously
described [35]. Serum high sensitivity interleukin-6 (IL-6)
and high sensitivity C-reactive protein will be measured as
biomarkers of inflammation. Serum high sensitivity IL-6
will be analysed using commercially available ELISA kits,
as previously described [36]. Serum high sensitivity C-
reactive protein will be analysed using routine laboratory
techniques at Fiona Stanley Hospital, Perth, WA. Partici-
pants will be asked to refrain from physical activity for 24-
h prior to providing a blood sample.
Anthropometry Anthropometric measurements will be
used to assess body composition using standard proto-
cols at each pre- and post-intervention visit. These mea-
sures will include height, weight, waist and hip
circumference, and body fat mass. Participants will be
wearing light clothing with no shoes or socks. Height
will be measured using a wall-mounted stadiometer to
the nearest 1 cm and body weight will be measured with
electronic scales to the nearest 0.01 kg. A steel tape
measure (W606PM; Lufkin Executive Thinline) will be
used to measure waist and hip circumference. Three
measurements will be taken for each site and the median
of the three values will be reported. Waist circumference
(cm) will be measured on bare skin at the narrowest part
of the waist. In the case of the narrowest part of the
waist not being visible, the waist will be measured mid-
way between the lowest rib and the iliac crest. Hip cir-
cumference (cm) will be measured at the greatest lateral
extension of the hips. Body fat mass will be measured
using bioelectrical impedance analysis (Tanita TBF-300
Total Body Composition Analyser) and skinfold mea-
surements. Skinfold callipers will be used to take skin-
fold measurements at the bicep and tricep sites.
Urine, blood, saliva, and oral bacteria collection Par-
ticipants will be provided with a sterilized container and
instructions to collect a 24-h urine sample which will
then be brought back into the clinic. Urine aliquots will
be stored at − 80 °C until analysis. Urine creatinine will
be measured using routine laboratory techniques at
Fiona Stanley Hospital, Perth, WA.
Fasting blood samples will be collected by venepunc-
ture. Total cholesterol, HDL cholesterol, triglycerides,
and glucose will be measured using routine laboratory
techniques at Fiona Stanley Hospital, Perth, WA. LDL
cholesterol will be calculated using the Friedewald for-
mula [37].
Saliva samples will be collected to assess salivary ni-
trate and nitrite concentrations and the nitrate to nitrite
reduction ratio [38]. To obtain the saliva sample, partici-
pants will be asked to expectorate into a specimen con-
tainer while sitting quietly for 5 min. Saliva aliquots will
be stored at − 80 °C.
A bacterial sample will be collected from the posterior
dorsal surface of the tongue using a sterile stainless-steel
metal tongue cleaner. The tongue cleaner will be scraped
over the dorsal surface of the tongue until a coating is
visible on the tongue cleaner (~ 5 times). This coating
will be removed from the tongue cleaner using a sterile
collection swab and frozen at − 80 °C for later isolation
of DNA.
Skin colour assessment Carotenoid deposition in adi-
pose tissue near the skin affects skin colour and has
been found to correlate with fruit and vegetable con-
sumption [39]. This will be measured as previously de-
scribed [39] before and after each intervention period.
Skin colour will be correlated with the Fruit and
Vegetable-Specific Food Frequency Questionnaire (FVS-
FFQ) and may provide a longer-term marker of fruit and
vegetable consumption, and hence compliance through-
out the 2-week intervention period. Eight different body
sites will be measured: the sole of the foot, shoulder,
right cheek, right bicep and tricep, the centre of the
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forehead, the back of the hand, and the palm of the
hand. A Spectro-Guide 4/50 Gloss 6801 spectrophotom-
eter with an 11mm diameter aperture (BYK Gardner,
Maryland, USA) will be used to measure the compos-
ition of the light that is reflected back from the skin after
exposure to a flash of white light. This will be done three
times at each session following calibration of the device
according to the manufacturer’s instructions.
Questionnaires Participants will be sent a link via email
to complete all study questionnaires online, except for the
Cancer Council of Victoria Food Frequency Questionnaire
(CCV-FFQ), the FVS-FFQ, and the flavonoids question-
naire, which will be completed at each participant’s first
baseline visit under the supervision of a nutritionist. At
each participant’s first baseline visit, participants will
complete the following questionnaires: 1) demographic
and lifestyle questionnaire, a self-administered question-
naire to assess demographic characteristics such as educa-
tion and previous smoking habits; 2) CCV-FFQ to
determine overall habitual dietary intake, a self-
administered semi-quantitative dietary questionnaire de-
veloped by the Cancer Council of Victoria, Australia [40];
3) FVS-FFQ to determine habitual fruit and vegetable in-
take, an interview-based detailed questionnaire to estimate
the consumption of fruits and vegetables; 4) flavonoids
questionnaire, a self-administered questionnaire to
estimate the consumption of foods and beverages rich in
flavan-3-ols; 5) beverages questionnaire, a self-
administered questionnaire used to estimate average
daily/weekly intake of 12 types of beverages (tea, herbal
tea, coffee, decaffeinated coffee, chocolate, fruit juice, soft
drinks, diet drinks, dairy milk, non-dairy milk, fruit and/or
vegetable smoothies, and water) and alcohol (beer, wine,
and spirits); 6) the Community Healthy Activities Model
Program for Seniors (CHAMPS), used to assess participa-
tion (activity type) and energy expenditure (intensity level)
of physical activities in older adults [41]; 7) the Longitu-
dinal Aging Study Amsterdam (LASA) questionnaire, a
self-administered questionnaire to assess sedentary behav-
iour of older adults [42]; and 8) Perceived Stress Scale
(PSS) questionnaire, a stress assessment instrument com-
piled of ten questions [43]. The CHAMPS, LASA, and
PSS questionnaires will be administered at the beginning
and end of each intervention period to monitor any
changes in activity and stress levels.
Online questionnaires will be checked for complete-
ness prior to participants coming in for their clinic visits.
Participants will be asked to provide any missing infor-
mation at their visit.
Data management
Data collection forms and protocols will be accessible to
study investigators in a secured shared drive. Data for
questionnaires and clinic visits will be entered electron-
ically by the study coordinator (ELC) and checked by
principal investigators (JHM and LCB). Only study in-
vestigators (ELC, JHM, LCB) will be able to access
password-protected participant data and all information
will remain confidential. To ensure confidentiality, data
disseminated to other study investigators will be de-
identified. Participant files will be locked and secured
outside working hours. Data sent off-site will be de-
identified to ensure confidentiality of participants.
Statistical methods
Statistical analyses will be performed using IBM SPSS
Statistics for Windows, version 25.0 (IBM Corp.,
Armonk, NY, USA) and STATA, version 16.0 (Statacorp,
College Station, TX, USA). Statistical significance will be
set at a 2-sided Type 1 error rate of P < 0.05. Descriptive
statistics of normally distributed continuous variables
will be expressed as mean ± standard deviation (SD),
non-normally distributed continuous variables as median
and interquartile range, and categorical variables as
number and proportion (%). The primary analyses will
be performed according to a modified intention to treat
protocol and will include all randomised participants for
which baseline data is obtained. Multilevel models will
be used to assess the effect of the dietary interventions
and these will produce unbiased estimates of the inter-
vention effects whenever there are small amounts of
missing data (i.e. < 10%). Where there is > 10% missing
data, multiple imputation will be used as a sensitivity
analysis. Covariates will be adjusted for in analyses as
necessary. Further exploratory analyses will be con-
ducted on those participants who fully comply to inter-
vention protocols (“per-protocol analyses”).
Monitoring
Data monitoring
The study coordinator (ELC) will oversee all aspects of
data monitoring with the assistance of principal investi-
gators (JMH and LCB). Due to the scale and short dur-
ation of this trial, a data monitoring committee is not
required. We also expect participants will have minimal
risks undertaking this trial; therefore, no interim ana-
lyses will be conducted.
Harms
We expect this trial will have minimal risks to partici-
pants. However, if any solicited or spontaneously adverse
events or other unintended effects of trial interventions
occur, this will be reported by the study coordinator
(ELC) to the principal investigators (JMH and LCB) in a
prompt manner. The principal investigators (JMH and
LCB) will then immediately report the event to the Edith
Cowan University Human Research Ethics Committee.
Connolly et al. Nutrition Journal           (2020) 19:41 Page 8 of 11
The outcome and actions taken will be recorded. Any
serious adverse events occurring on site resulting in
death will be reported immediately within 24 h and any
serious AE occurring on site resulting in other circum-
stances other than death will be reported immediately
within 72 h. All reports will be followed promptly by de-
tailed written reports. The immediate reports and
follow-up reports will identify the participant by a
unique code number assigned to the trial participant ra-
ther than by the participant’s name, personal identifica-
tion number, and/or addresses.
Ethics and dissemination
Research ethics approval
Ethics approval has been granted by the Edith Cowan
University Human Research Ethics Committee (approval
number: 2019–00356-BLEKKENHORST).
Protocol amendments
Any modifications to study objectives, study design, par-
ticipant population, sample size, study procedures, or
significant administrative aspects will require an amend-
ment to the protocol. Amendments will be agreed upon
by study investigators and approved by the Edith Cowan
University Human Research Ethics Committee prior to
implementation.
Consent or assent
Prior to the study commencing, participants will receive
an information pack detailing the trial and what is ex-
pected of participation. The study coordinator (ELC) will
then have an informed discussion with participants and
answer any questions the individual has regarding the
trial. The study coordinator (ELC) will then obtain written
consent from those willing to participate in the trial. Con-
sent will be obtained for collection and use of participant
data and biological specimens in ancillary studies.
Confidentiality
To ensure confidentiality, participants will be identified
by a coded identification number. This coded identifica-
tion number will be used to identify all laboratory speci-
mens, data collection, and administrative forms to
maintain participant confidentiality. All study investiga-
tors and staff will be made aware of the need for
complete confidentiality when dealing with participant
information. All information related to the study will be
stored securely at the study site. All records that contain
personal identifiers will be stored in a locked filing cabi-
net in a limited-access area. All databases will be secured
with password-protected access systems.
Access to data
The study coordinator (ELC) and principal investigators
(JMH and LCB) will have access to the cleaned datasets.
Principal investigators (JMH and LCB) will oversee
intra-study data sharing. To ensure confidentiality, data
shared amongst other study investigators will be de-
identified.
Ancillary and post-trial care
We expect this trial will have minimal risks to partici-
pants. However, if a serious or unexpected adverse event
related to trial procedures occurs, participants will have
provisional care beyond that immediately required.
Dissemination policy
Data from this trial will not be presented in public or
submitted for publication without permission of the
principal investigators (JMH and LCB). On permission
of principal investigators (JMH and LCB), results of this
trial will be disseminated via scientific symposia and
conferences and will be published in peer-review scien-
tific journals. The requirements for authorship will ad-
here to scientific journal guidelines.
Discussion
Preventative strategies are needed to mitigate the in-
creasing prevalence of cardiovascular disease and type
2 diabetes. Diet is an important modifiable risk factor
for the development of these conditions. Although
the health benefits of vegetables are widely accepted,
intakes of vegetables are often well below established
guidelines, and intakes of vegetables linked to cardio-
vascular health benefits are often very limited. Therefore,
the recommendation of specific types of vegetables may
be warranted.
This paper outlines the protocol for a randomised
controlled trial that will evaluate the impact of in-
creasing cruciferous vegetables in a population with
mildly elevated blood pressure. In this study, a com-
prehensive collection of vascular and metabolic out-
comes will be measured to evaluate the benefit of
cruciferous vegetables in comparison with more com-
monly consumed vegetables. The results of this trial
will inform the direction of future research investigat-
ing the effect of cruciferous vegetables on cardiometa-
bolic health outcomes and may contribute to the
revision of dietary and clinical guidelines.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12937-020-00559-3.
Additional file 1. SPIRIT checklist.
Additional file 2. Participant information and consent form.
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